

Fernando Cabanillas

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2028711/fernando-cabanillas-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

189
papers

10,899
citations

46
h-index

101
g-index

191
ext. papers

11,607
ext. citations

3.5
avg, IF

5.12
L-index

#	Paper	IF	Citations
189	Single-Arm, Open-Label Phase 2 Trial of Preemptive Methylprednisolone to Avert Progression to Respiratory Failure in High-Risk Patients with COVID-19 2021 ,		1
188	Evaluation of the MD Anderson tumor score for diffuse large B-cell lymphoma in the rituximab era. <i>European Journal of Haematology</i> , 2020 , 104, 400-408	3.8	1
187	Gastric MALT Lymphoma with Biclonal Gammopathy and Bone Marrow Involvement Mimicking Multiple Myeloma. <i>Puerto Rico Health Sciences Journal</i> , 2020 , 39, 275-277	0.5	
186	Incidence and Risk Factors for Developing Herpes Zoster Among a Cohort of Patients Diagnosed With Lymphoma at a Community Cancer Center. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, e153-e158	2	3
185	A New Salvage Regimen for Aggressive Lymphomas Based on Gemcitabine, Rituximab, and Oxaliplatin Followed by Lenalidomide (GROC-Rev). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, 776-783	2	1
184	Mantle Cell Lymphoma with t(11;22) (q13;q11.2) an indolent clinical variant?. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2509-2511	1.9	5
183	Successful Use of Bortezomib-Lenalidomide Combination as Treatment for a Patient With Plasmablastic Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018 , 18, e275-e277	2	4
182	Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2017 , 178, 250-256	4.5	22
181	High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study. <i>British Journal of Haematology</i> , 2017 , 177, 263-270	4.5	12
180	Results of Upfront Therapy for Marginal Zone Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17, 879-883	2	3
179	Check this checkpoint inhibitor in lymphoma. <i>Blood</i> , 2017 , 130, 234-235	2.2	2
178	Advances in Diagnosis and Management of Diffuse Large B-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17, 783-796	2	23
177	Indolent Lymphomas That Present With Clinically Aggressive Features: A Subset of Low-Grade Lymphomas With a Behavior Inconsistent With the Histologic Diagnosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016 , 16, 550-557	2	7
176	Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β_2 -microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model. <i>British Journal of Haematology</i> , 2016 , 175, 290-299	4.5	21
175	Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center. <i>British Journal of Haematology</i> , 2016 , 172, 80-8	4.5	67
174	In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. <i>Mayo Clinic Proceedings</i> , 2015 , 90, 996-1000	6.4	105
173	Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma. <i>British Journal of Haematology</i> , 2014 , 166, 920-8	4.5	11

172	Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®)) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas. <i>British Journal of Haematology</i> , 2013 , 162, 631-8	4.5	22
171	Recent advances in the management of mantle cell lymphoma. <i>Current Opinion in Oncology</i> , 2013 , 25, 716-21	4.2	6
170	Curability of advanced indolent or low-grade follicular lymphomas: time for a new paradigm?. <i>Journal of Clinical Oncology</i> , 2013 , 31, 14-6	2.2	17
169	Reply to I.E. Haines. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1798	2.2	
168	Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. <i>Lancet Oncology, The</i> , 2012 , 13, 716-23	21.7	227
167	Pixantrone: a new agent for relapsed aggressive lymphomas. <i>Lancet Oncology, The</i> , 2012 , 13, 654-6	21.7	2
166	Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas. <i>Leukemia and Lymphoma</i> , 2012 , 53, 50-6	1.9	22
165	Front-line immunochemotherapy for aggressive non-Hodgkin lymphoma using dose-dense rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone plus granulocyte-macrophage colony stimulating factor and pegfilgrastim as support. <i>Leukemia and Lymphoma</i> , 2012 , 53, 1929-33	1.9	1
164	New developments in the field of diffuse large cell lymphoma. <i>Hematology</i> , 2012 , 17 Suppl 1, S98-100	2.2	1
163	Rectal adenocarcinoma: proposal for a model based on pretreatment prognostic factors. <i>Puerto Rico Health Sciences Journal</i> , 2012 , 31, 52-8	0.5	
162	Non-Hodgkin's lymphoma: the old and the new. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011 , 11 Suppl 1, S87-90	2	12
161	Rituximab in DLBCL: 6 years on. <i>Lancet Oncology, The</i> , 2011 , 12, 984-5	21.7	3
160	Successful treatment of a patient with Epstein-Barr virus-positive B-cell lymphoproliferative disorder resembling post-transplant lymphoproliferative disorder using single-agent rituximab. <i>Journal of Clinical Oncology</i> , 2011 , 29, e658-60	2.2	4
159	Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. <i>British Journal of Haematology</i> , 2010 , 150, 200-8	4.5	168
158	How important is whole brain radiotherapy for treatment of primary CNS lymphoma?. <i>Lancet Oncology, The</i> , 2010 , 11, 1011-2	21.7	10
157	Front-line management of diffuse large B cell lymphoma. <i>Current Opinion in Oncology</i> , 2010 , 22, 642-5	4.2	22
156	Epigenetic therapy of lymphoma using histone deacetylase inhibitors. <i>Clinical and Translational Oncology</i> , 2010 , 12, 401-9	3.6	32
155	Therapeutic concepts in mantle cell lymphoma. <i>European Journal of Haematology</i> , 2010 , 85, 371-86	3.8	3

154	Marginal zone lymphomas: factors that affect the final outcome. <i>Cancer</i> , 2010 , 116, 4291-8	6.4	37
153	Vitamin C and cancer: what can we conclude--1,609 patients and 33 years later?. <i>Puerto Rico Health Sciences Journal</i> , 2010 , 29, 215-7	0.5	12
152	Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma. <i>Cancer</i> , 2008 , 113, 2734-41	6.4	29
151	The Baseline PET SUV Correlates Better with Clinical Outcome Than the Post-Therapy PET Scan in Previously Untreated Patients with Histologically Aggressive Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2008 , 112, 3588-3588	2.2	2
150	Rituximab (R) + Hypercvad Alternating with R-Methotrexate/Cytarabine after 9 Years: Continued High Rate of Failure-Free Survival in Untreated Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2008 , 112, 833-833	2.2	7
149	Dose dense CHOP: when more is not always better!. <i>Leukemia and Lymphoma</i> , 2007 , 48, 845-6	1.9	2
148	Variations in chemotherapy and radiation therapy in a large nationwide and community-based cohort of elderly patients with non-Hodgkin lymphoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2007 , 30, 163-71	2.7	13
147	Historical Perspective on the Treatment Challenges of Low-Grade Non-Hodgkin Lymphoma. <i>Seminars in Hematology</i> , 2007 , 44, S2-S6	4	1
146	Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis. <i>European Journal of Haematology</i> , 2006 , 77, 387-94	3.8	35
145	Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. <i>Cancer</i> , 2006 , 106, 120-7	6.4	73
144	Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. <i>Cancer</i> , 2006 , 106, 1569-80	6.4	441
143	Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. <i>Journal of Clinical Oncology</i> , 2006 , 24, 1582-9	2.2	175
142	Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2006 , 47, 1818-21	1.9	5
141	A prospective randomized study to compare the molecular response rates between central lymphatic irradiation and intensive alternating triple chemotherapy in the treatment of stage I-III follicular lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005 , 63, 188-93	4	6
140	Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen. <i>Cancer</i> , 2005 , 104, 345-53	6.4	19
139	The role of mitoxantrone in the treatment of indolent lymphomas. <i>Oncologist</i> , 2005 , 10, 150-9	5.7	45
138	Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 2005 , 23, 667-75	2.2	465
137	Evaluation of Breast Imaging Reporting and Data System Category 3 mammograms and the use of stereotactic vacuum-assisted breast biopsy in a nonacademic community practice. <i>Cancer</i> , 2004 , 100, 710-4	6.4	17

136	Thalidomide for patients with recurrent lymphoma. <i>Cancer</i> , 2004 , 100, 1186-9	6.4	27
135	Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy. <i>Leukemia and Lymphoma</i> , 2004 , 45, 2085-92	1.9	34
134	Establishment and characterization of a new mantle cell lymphoma cell line M-1. <i>Leukemia and Lymphoma</i> , 2004 , 45, 1255-60	1.9	5
133	Second malignancies after chemotherapy and radiotherapy for Hodgkin disease. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004 , 27, 73-80	2.7	23
132	Molecular response of follicular lymphoma to cyclophosphamide, doxorubicin, vincristine, prednisone C(H)OP or COP-based therapy as measured by polymerase chain reaction evidence of translocation (14;18)(q32;q21). <i>Cancer Journal (Sudbury, Mass)</i> , 2004 , 10, 49-53	2.2	
131	Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. <i>Blood</i> , 2004 , 104, 1624-30	2.2	202
130	Importance of esophagogastroduodenoscopy in the evaluation of non-gastrointestinal mucosa-associated lymphoid tissue lymphoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2003 , 9, 321-4	2.2	16
129	Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. <i>Cancer</i> , 2003 , 97, 586-91	6.4	202
128	Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy. <i>Cancer</i> , 2003 , 98, 1021-8	6.4	18
127	Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003 , 55, 36-43	4	28
126	Central lymphatic irradiation for stage I-III follicular lymphoma: report from a single-institutional prospective study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003 , 57, 316-20	4	14
125	Stage III follicular lymphoma: long-term follow-up and patterns of failure. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003 , 57, 748-54	4	11
124	Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2115-22	2.2	106
123	Expression of CD40 ligand (CD154) in B and T lymphocytes of Hodgkin disease: potential therapeutic significance. <i>Cancer</i> , 2002 , 94, 1-5	6.4	38
122	Results with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone followed by radiotherapy with or without prechemotherapy surgical debulking for patients with bulky, aggressive lymphoma. <i>Cancer</i> , 2002 , 94, 601-5	6.4	6
121	European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease. <i>Cancer</i> , 2002 , 94, 1731-8	6.4	59
120	International prognostic index-based outcomes for diffuse large B-cell lymphomas. <i>Cancer</i> , 2002 , 94, 3083-8	6.4	42
119	An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease. <i>Cancer</i> , 2002 , 95, 2534-8	6.4	32

118	Primary cutaneous non-Hodgkin's lymphoma with aggressive histology: inferior outcome is associated with peripheral T-cell type and elevated lactate dehydrogenase, but not extent of cutaneous involvement. <i>Annals of Oncology</i> , 2002 , 13, 1290-9	10.3	4
117	Trimetrexate in relapsed T-cell lymphoma with skin involvement. <i>Journal of Clinical Oncology</i> , 2002 , 20, 2876-80	2.2	22
116	Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 2002 , 20, 2453-63	2.2	936
115	Apoptotic rate in peripheral T-cell lymphomas. A study using a tissue microarray with validation on full tissue sections. <i>American Journal of Clinical Pathology</i> , 2002 , 118, 328-34	1.9	58
114	Quantitative real-time polymerase chain reaction for detection of circulating cells with t(14;18) in volunteer blood donors and patients with follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2002 , 43, 1589-98	1.9	11
113	Is there an increased rate of additional malignancies in patients with mantle cell lymphoma?. <i>Annals of Oncology</i> , 2002 , 13, 318-22	10.3	18
112	Radiotherapy alone for lymphocyte-predominant Hodgkin's disease. <i>Cancer Journal (Sudbury, Mass)</i> , 2002 , 8, 377-83	2.2	53
111	BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. <i>Blood</i> , 2002 , 100, 3935-41	2.2	81
110	Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma. <i>Blood</i> , 2002 , 100, 4351-7	2.2	54
109	Outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2002 , 43, 1769-75	1.9	9
108	Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. <i>Blood</i> , 2001 , 98, 2784-90	2.2	110
107	Interleukin-13 levels in serum from patients with Hodgkin disease and healthy volunteers. <i>Blood</i> , 2001 , 98, 2877-8	2.2	19
106	The significance of molecular response of follicular lymphoma to central lymphatic irradiation as measured by polymerase chain reaction for t(14;18)(q32;q21). <i>International Journal of Radiation Oncology Biology Physics</i> , 2001 , 49, 727-32	4	9
105	Long-term results with radiotherapy for Stage I-II follicular lymphomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001 , 51, 1219-27	4	131
104	Hematologic recovery after central lymphatic irradiation for patients with stage I-III follicular lymphoma. <i>Cancer</i> , 2001 , 92, 1074-9	6.4	4
103	Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma. <i>Cancer</i> , 2001 , 91, 2440-2446	6.4	21
102	Mantle irradiation alone for pathologic stage I and II Hodgkin's disease: long-term follow-up and patterns of failure. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001 , 50, 971-7	4	14
101	Differential expression of BCL-2 family proteins in ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null-cell lineage. <i>American Journal of Pathology</i> , 2001 , 159, 527-35	5.8	84

100	Mantle-cell lymphoma. <i>Lancet Oncology, The</i> , 2001 , 2, 141-8	21.7	80
99	Primary effusion lymphoma in an HIV-negative patient with no serologic evidence of Kaposi's sarcoma virus. <i>Leukemia and Lymphoma</i> , 2001 , 41, 185-9	1.9	24
98	The outcome of combined-modality treatments for stage I and II primary large B-cell lymphoma of the mediastinum. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000 , 47, 1281-5	4	23
97	Mucosa-associated lymphoid tissue lymphoma with initial supradiaphragmatic presentation: natural history and patterns of disease progression. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000 , 48, 399-403	4	19
96	Detection of chromosome 11q13 breakpoints by interphase fluorescence in situ hybridization. A useful ancillary method for the diagnosis of mantle cell lymphoma. <i>American Journal of Clinical Pathology</i> , 2000 , 114, 248-57	1.9	42
95	Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients. <i>Leukemia and Lymphoma</i> , 2000 , 39, 77-85	1.9	56
94	Managing Indolent Lymphomas in Relapse. <i>Hematology American Society of Hematology Education Program</i> , 2000 , 2000, 166-179	3.1	1
93	Managing Indolent Lymphomas in Relapse. <i>Hematology American Society of Hematology Education Program</i> , 2000 , 2000, 166-179	3.1	
92	Hematopoietic retroviral gene marking in patients with follicular non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 1999 , 32, 279-88	1.9	18
91	Correlation of Bcl-2 Rearrangement With Clinical Characteristics and Outcome in Indolent Follicular Lymphoma. <i>Blood</i> , 1999 , 93, 3081-3087	2.2	114
90	Primary non-Hodgkin lymphoma of the small bowel. <i>Radiology</i> , 1999 , 211, 183-7	20.5	20
89	Apoptosis and the Bcl-2 gene family -- patterns of expression and prognostic value in stage I and II follicular center lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999 , 44, 19-29	4	18
88	Salvage central lymphatic irradiation in follicular lymphomas following failure of chemotherapy: a feasibility study. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999 , 45, 1207-12	4	1
87	Phase II study of paclitaxel in combination with mitoxantrone and ifosfamide/mesna for patients with relapsed or refractory non-Hodgkin's lymphoma after failure to cytarabine/cisplatin combination. <i>Investigational New Drugs</i> , 1999 , 17, 187-92	4.3	4
86	Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. <i>Journal of Clinical Oncology</i> , 1999 , 17, 1244	2.2	2910
85	Correlation of Bcl-2 Rearrangement With Clinical Characteristics and Outcome in Indolent Follicular Lymphoma. <i>Blood</i> , 1999 , 93, 3081-3087	2.2	7
84	Subdiaphragmatic stage I & II Hodgkin's disease: long-term follow-up and prognostic factors. <i>International Journal of Radiation Oncology Biology Physics</i> , 1998 , 41, 1047-56	4	19
83	Unbalanced expression of Fas and CD40 in mantle cell lymphoma. <i>British Journal of Haematology</i> , 1998 , 103, 217-9	4.5	22

82	Coexpression of CD40 and CD40 ligand in B-cell lymphoma cells. <i>British Journal of Haematology</i> , 1998 , 103, 270-5	4.5	42
81	Paclitaxel plus high-dose cyclophosphamide with G-CSF support in patients with relapsed and refractory aggressive non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 1998 , 103, 678-83	4.5	8
80	Hodgkin's disease: correlation of clinical characteristics with probabilities for negative lymphangiogram vs. negative laparotomy findings in patients with Stage I supradiaphragmatic presentations vs. those in patients with Stage II. <i>International Journal of Radiation Oncology Biology Physics</i> , 1998 , 40, 377-86	4	2
79	COINCIDENT RENAL CELL CARCINOMA AND NONHODGKIN'S LYMPHOMA: THE M.D. ANDERSON EXPERIENCE AND REVIEW OF THE LITERATURE. <i>Journal of Urology</i> , 1998 , 159, 714-717	2.5	52
78	Novel 5' exonuclease-based real-time PCR assay for the detection of t(14;18)(q32;q21) in patients with follicular lymphoma. <i>American Journal of Pathology</i> , 1998 , 153, 63-8	5.8	107
77	Tumor necrosis factor-alpha and interferon-gamma, but not HTLV-I tax, are likely factors in the epidermotropism of cutaneous T-cell lymphoma via induction of interferon-inducible protein-10. <i>Leukemia and Lymphoma</i> , 1998 , 29, 315-28	1.9	19
76	Apoptotic induction in transformed follicular lymphoma cells by Bcl-2 downregulation. <i>Leukemia and Lymphoma</i> , 1998 , 30, 367-79	1.9	26
75	High serum interleukin-6 levels correlate with a shorter failure-free survival in indolent lymphoma. <i>Leukemia and Lymphoma</i> , 1998 , 30, 563-71	1.9	39
74	The Clinical Significance of Molecular Response in Indolent Follicular Lymphomas. <i>Blood</i> , 1998 , 91, 2955-2960		126
73	Localized primary non-Hodgkin lymphoma of the breast. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1998 , 21, 376-80	2.7	69
72	Phase I study of fludarabine and paclitaxel for the treatment of low-grade non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 1997 , 26, 77-82	1.9	12
71	Soluble CD95 in the serum of patients with low and intermediate grade malignant lymphomas: absence of prognostic correlations. <i>Leukemia and Lymphoma</i> , 1997 , 27, 517-21	1.9	11
70	Primary parotid lymphoma: the effect of International Prognostic Index on outcome. <i>Leukemia and Lymphoma</i> , 1997 , 26, 49-56	1.9	24
69	Long-term follow-up of platinum-based lymphoma salvage regimens. The M.D. Anderson Cancer Center experience. <i>Hematology/Oncology Clinics of North America</i> , 1997 , 11, 937-47	3.1	42
68	Primary ovarian non-Hodgkin's lymphoma: outcome after treatment with combination chemotherapy. <i>Gynecologic Oncology</i> , 1997 , 64, 446-50	4.9	90
67	Long-term outcome of treatment for Ann Arbor Stage I Hodgkin's disease: prognostic factors for survival and freedom from progression. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997 , 38, 593-9	4	9
66	Localized primary malignant lymphoma of bone. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997 , 37, 1087-93	4	81
65	Long-term outcome of treatment for Ann Arbor stage 1 Hodgkin's disease: patterns of failure, late toxicity and second malignancies. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997 , 39, 609-16	4	30

64	Analysis of p53 gene deletions in patients with non-Hodgkin's lymphoma by dual-colour fluorescence in-situ hybridization. <i>British Journal of Haematology</i> , 1997 , 98, 913-21	4.5	15
63	Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. <i>British Journal of Haematology</i> , 1997 , 99, 618-24	4.5	112
62	Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial. <i>British Journal of Haematology</i> , 1997 , 96, 328-32	4.5	33
61	Lymphoma of the nasal cavity and paranasal sinuses: improved outcome and altered prognostic factors with combined modality therapy. <i>Cancer</i> , 1997 , 80, 477-88	6.4	116
60	T-Cell Rich B-Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 1997 , 21, 499-500	6.7	
59	Hodgkin's disease variant of Richter's syndrome: experience at a single institution. <i>Leukemia and Lymphoma</i> , 1996 , 23, 333-7	1.9	49
58	Interferon-inducible protein-10 and the pathogenesis of cutaneous T-cell lymphomas. <i>Leukemia and Lymphoma</i> , 1996 , 24, 103-10	1.9	9
57	Endocrine characterization of primary mediastinal lymphoma. <i>Leukemia and Lymphoma</i> , 1996 , 23, 613-5	1.9	2
56	CD30 ligand is expressed on resting normal and malignant human B lymphocytes. <i>British Journal of Haematology</i> , 1996 , 93, 569-71	4.5	58
55	T-cell-rich B large-cell lymphoma simulating lymphocyte-rich Hodgkin's disease. <i>American Journal of Surgical Pathology</i> , 1996 , 20, 193-201	6.7	62
54	Significance of tumor size and radiation dose to local control in stage I-III diffuse large cell lymphoma treated with CHOP-Bleo and radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 1995 , 31, 3-11	4	41
53	Chromosome X numerical abnormalities in patients with non-Hodgkin's lymphoma. A study of 59 patients using fluorescence in situ hybridization. <i>Cancer Genetics and Cytogenetics</i> , 1995 , 82, 23-9		6
52	Risk classification for large cell lymphoma using lactate dehydrogenase, beta-2 microglobulin, and thymidine kinase. <i>Leukemia and Lymphoma</i> , 1995 , 18, 87-92	1.9	16
51	Rising serum lactate dehydrogenase often caused by granulocyte-or Granulocyte-macrophage colony stimulating factor and not tumor progression in patients with lymphoma or myeloma. <i>Leukemia and Lymphoma</i> , 1995 , 17, 473-7	1.9	17
50	16-year experience at M. D. Anderson Cancer Center with primary Ki-1 (CD30) antigen expression and anaplastic morphology in adult patients with diffuse large cell lymphoma. <i>Leukemia and Lymphoma</i> , 1995 , 20, 97-102	1.9	11
49	Outcome of Hodgkin's disease in elderly patients. <i>Hematological Oncology</i> , 1995 , 13, 19-27	1.3	25
48	Simultaneous presentation of hairy cell leukemia and follicular small cleaved cell lymphoma in a patient with previous diagnosis of renal cell carcinoma. <i>Hematological Oncology</i> , 1995 , 13, 63-7	1.3	9
47	Lymphomatous presentation of CD4+/CD8+ HTLV-1-related adult T-cell leukemia/lymphoma in an Iranian woman. <i>Leukemia and Lymphoma</i> , 1994 , 12, 471-6	1.9	5

46	A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas. <i>Investigational New Drugs</i> , 1994 , 12, 217-22	4.3	1
45	Polysomy of chromosome 12 in 60 patients with non-Hodgkin's lymphoma assessed by fluorescence in situ hybridization: differences between follicular and diffuse large cell lymphoma. <i>Genes Chromosomes and Cancer</i> , 1994 , 9, 161-7	5	17
44	Primary mediastinal large cell lymphoma. <i>Hematological Oncology</i> , 1994 , 12, 175-84	1.3	22
43	High incidence of monosomy 18 in lymphoid malignancies that have bone marrow and peripheral blood involvement. <i>Cancer Genetics and Cytogenetics</i> , 1994 , 77, 39-44		8
42	The expanding role of fludarabine in hematologic malignancies. <i>Leukemia and Lymphoma</i> , 1994 , 14 Suppl 2, 11-6	1.9	24
41	Use of retroviral markers to identify efficacy of purging and origin of relapse following autologous bone marrow and peripheral blood cell transplantation in indolent B cell neoplasms (follicular non-Hodgkin's lymphoma or chronic lymphocytic leukemia (CLL) patients). <i>Human Gene Therapy</i> , 1993 , 4, 821-31	4.8	9
40	What constitutes a "cure" in lymphoma?. <i>Leukemia and Lymphoma</i> , 1993 , 11, 161-3	1.9	5
39	Human B cell lymphomas: in vitro and in vivo studies on growth factors and cell growth. <i>Leukemia and Lymphoma</i> , 1993 , 10 Suppl, 51-6	1.9	3
38	Cisplatin-CBV with autologous bone marrow transplantation for relapsed Hodgkin's disease. <i>Leukemia and Lymphoma</i> , 1993 , 9, 71-7	1.9	6
37	Frontline Management of Intermediate Grade Lymphomas at M. D. Anderson Hospital. <i>Leukemia and Lymphoma</i> , 1992 , 7, 70-71	1.9	
36	Radiotherapy during pregnancy for clinical stages IA-IIA Hodgkin's disease. <i>International Journal of Radiation Oncology Biology Physics</i> , 1992 , 23, 407-12	4	107
35	Accuracy of diagnosis of malignant lymphoma by combining fine-needle aspiration cytology with immunocytochemistry and in selected cases, Southern blotting of aspirated cells: a tissue-controlled study of 86 patients. <i>Diagnostic Cytopathology</i> , 1992 , 8, 456-64	1.4	59
34	Chromosomal abnormalities in adult non-endemic Burkitt's lymphoma and leukemia: 22 new reports and a review of 148 cases from the literature. <i>Hematological Oncology</i> , 1991 , 9, 63-78	1.3	43
33	Beta-lactam regimens for the febrile neutropenic patient. <i>Cancer</i> , 1990 , 65, 9-16	6.4	46
32	Surgical debulking is associated with improved survival in stage I-II diffuse large cell lymphoma. <i>Cancer</i> , 1990 , 66, 267-72	6.4	35
31	Philadelphia chromosome without breakpoint cluster region rearrangement in a case of Lennert's lymphoma of suppressor phenotype. <i>Hematological Oncology</i> , 1989 , 7, 189-94	1.3	5
30	Refractoriness to chemotherapy and poor survival related to abnormalities of chromosomes 17 and 7 in lymphoma. <i>American Journal of Medicine</i> , 1989 , 87, 167-72	2.4	63
29	Fine-needle aspiration cytology of peripheral T-cell lymphoma. A cytologic, immunologic, and cytometric study. <i>American Journal of Clinical Pathology</i> , 1989 , 91, 120-31	1.9	64

28	A review and interpretation of cytogenetic abnormalities identified in Hodgkin's disease. <i>Hematological Oncology</i> , 1988 , 6, 271-4	1.3	23
27	The adjuvant role of two cycles of MOPP and low-dose lung irradiation in stage IA through IIB Hodgkin's disease: preliminary results. <i>International Journal of Radiation Oncology Biology Physics</i> , 1988 , 14, 683-92	4	21
26	Randomized trial of beta-lactam regimens in febrile neutropenic cancer patients. <i>American Journal of Medicine</i> , 1988 , 84, 581-9	2.4	58
25	Monosomy 21, partial duplication of chromosome 11, and structural abnormality of chromosome 1q21 in a case of lymphoma developing in a transplant recipient: characteristic abnormalities of secondary lymphoma?. <i>Cancer Genetics and Cytogenetics</i> , 1987 , 24, 7-10		10
24	HLA class II antigen associated invariant chain gene expression in malignant lymphoma. <i>British Journal of Haematology</i> , 1987 , 67, 413-7	4.5	3
23	Central nervous system prophylaxis with combined intravenous and intrathecal methotrexate in diffuse lymphoma of aggressive histologic type. <i>Cancer</i> , 1986 , 57, 971-7	6.4	41
22	Stage I-II follicular lymphoma. Treatment results for 76 patients. <i>Cancer</i> , 1986 , 58, 1596-602	6.4	90
21	9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma. <i>Cancer Chemotherapy and Pharmacology</i> , 1986 , 18, 145-52	3.5	61
20	High dose therapy and autologous marrow transplantation as salvage treatment for patients with diffuse large cell lymphoma. <i>European Journal of Cancer & Clinical Oncology</i> , 1986 , 22, 871-7		29
19	Chromosomal abnormalities in lymphoma and their correlations with nucleic acid flow cytometry. <i>Cancer Genetics and Cytogenetics</i> , 1986 , 21, 99-106		18
18	Chemotherapy as definitive treatment of stage I-II large cell and diffuse mixed lymphomas. <i>Hematological Oncology</i> , 1985 , 3, 25-31	1.3	45
17	Human interferon alpha in malignant lymphoma and Hodgkin's disease. Results of the American Cancer Society trial. <i>Cancer</i> , 1985 , 56, 1305-10	6.4	83
16	Benign fibrous histiocytoma in Hodgkin's disease. <i>Cancer Investigation</i> , 1984 , 2, 347-50	2.1	
15	The hematologic malignancies. Leukemia, lymphoma, and myeloma. <i>Cancer</i> , 1984 , 54, 2741-50	6.4	7
14	Effects of intensive induction chemotherapy for extensive-disease small cell bronchogenic carcinoma in protected environment-prophylactic antibiotic units. <i>American Journal of Medicine</i> , 1984 , 76, 405-12	2.4	17
13	Human central nervous system pharmacology of pentamethylmelamine and its metabolites. <i>Journal of Neuro-Oncology</i> , 1983 , 1, 357-64	4.8	22
12	Ventricular fibrillation following AMSA. Uncomplicated retreatment following correction of hypokalemia. <i>Cancer</i> , 1983 , 52, 557-8	6.4	14
11	Sequential chemotherapy and late intensification for malignant lymphomas of aggressive histologic type. <i>American Journal of Medicine</i> , 1983 , 74, 382-8	2.4	52

10	Study of the natural history of immunoblastic lymphadenopathy and atypical immunoproliferative disorders. <i>Cancer Investigation</i> , 1983 , 1, 293-9	2.1	7
9	Management with chemotherapy only of stage I and II malignant lymphoma of aggressive histologic types. <i>Cancer</i> , 1980 , 46, 2356-9	6.4	94
8	Intensive induction chemotherapy of extensive small cell bronchogenic carcinoma in protected environment--prophylactic antibiotic units. A preliminary report. <i>International Journal of Radiation Oncology Biology Physics</i> , 1980 , 6, 1087-92	4	17
7	Protected environment-prophylactic antibiotic program for malignant lymphoma. Randomized trial during chemotherapy to induce remission. <i>American Journal of Medicine</i> , 1979 , 66, 74-81	2.4	38
6	Nodular malignant lymphomas: factors affecting complete response rate and survival. <i>Cancer</i> , 1979 , 44, 1983-9	6.4	37
5	Effective combination chemotherapy of adult malignant histiocytosis (histiocytic medullary reticulosis). <i>Medical and Pediatric Oncology</i> , 1978 , 4, 29-34		10
4	Improvement in complete response rate, duration of response and survival with adriamycin combination chemotherapy for non-Hodgkin lymphoma: a prognostic factor comparison of two regimens. <i>Medical and Pediatric Oncology</i> , 1978 , 4, 321-31		5
3	Factors Predicting for Response and Survival in Adults With Advanced Non-Hodgkin's Lymphoma. <i>Archives of Internal Medicine</i> , 1978 , 138, 413		58
2	Comparison of lymphangiograms and gallium scans in the non-Hodgkin's lymphomas. <i>Cancer</i> , 1977 , 39, 85-8	6.4	13
1	Nephrotoxicity of Combined Cephalothin-Gentamicin Regimen. <i>Archives of Internal Medicine</i> , 1975 , 135, 850		31